Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. (Vulvar-AIN)
Vulvar Cancer, Cervical Cancer, Vulvar Dysplasia
About this trial
This is an interventional screening trial for Vulvar Cancer focused on measuring Vulvar Cancer, Cervical Cancer, Vulvar Dysplasia, Cervical Dysplasia, Anal Cancer, Anal Dysplasia, HPV
Eligibility Criteria
Inclusion Criteria:
- Women age ≥ 40
- Previous diagnosis of VIN 2/3 or vulvar
Exclusion Criteria:
- Women with a previous diagnosis of cancer aside from basal cell carcinoma of the skin, cervical cancer, or vulvar cancer
- Women who are HIV positive
- Women currently taking immunosuppressant medication
- Women who have had a previous hysterectomy
Sites / Locations
- Odette Cancer CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Screening anal Pap Smear - Negative (75%)
Screening anal Pap Smear - Negative (25%)
Screening anal Pap Smear - Positive
All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.